Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Dizal Discovered First-0f-its-kind Sunvozertinib Treatment

Dizal has discovered sunvozertinib as a groundbreaking first-line treatment for individuals with locally advanced or metastatic non-small cell lung cancer (NSCLC) carrying epidermal growth factor receptor (EGFR) exon 20 insertion (Exon20ins) mutations.

Sunvozertinib's unique molecular structure allows it to address the inherent challenges of targeting EGFR Exon20ins mutations, delivering enhanced efficacy, safety, and administration convenience. 

Based on data from the multicenter phase 2 pivotal study WU-KONG6, sunvozertinib has received approval in China for the treatment of adult patients with locally advanced or metastatic NSCLC who have EGFR exon 20 insertion mutations and whose disease has advanced after receiving platinum-based chemotherapy. 

This validation underscores its potent and well-tolerated profile in previously treated NSCLC patients with EGFR Exon20ins mutations, with sunvozertinib exhibiting a well-tolerated and manageable safety profile in clinical settings.

The approval is anchored in the results of the WU-KONG6 study, the pivotal investigation of sunvozertinib in NSCLC patients pretreated with platinum-based chemotherapy and carrying EGFR exon20ins mutations. The primary endpoint of the study, confirmed the overall response rate (cORR).

Significant anti-tumor efficacy was evident across various EGFR exon20ins subtypes, and notably, in patients with pretreated and stable brain metastasis. 

Additionally, sunvozertinib exhibited promising anti-tumor activity in NSCLC patients with EGFR sensitizing mutations, T790M mutations, uncommon mutations (such as G719X, L861Q, etc.), as well as HER2 exon20ins mutations.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024